By Daniella Parra Avertix Medical announced that Professor Ian Meredith AM will join the Board of Directors, bringing extensive experience as a renowned interventional cardiologist and global medical executive, the company said. “Avertix has a meaningful product that holds the...

By Daniella Parra Promontory Therapeutics, a clinical stage pharmaceutical company focused on oncology, said it treated its first four patients in France for late-stage metastatic castration-resistant prostate cancer (mCRPC). The study is being led by oncologist Dr. Karim Fizazi at...

By Daniella Parra Eterna Therapeutics Inc. (Nasdaq: ERNA), announced the successful completion of a private placement transaction, generating approximately $8.7 million. The notes, bearing a 6.0% annual interest rate and maturing in July 2028, can be converted into Eterna common...

By Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) announced positive Phase 1 clinical trial results for their investigational immunotherapeutic, UB-312, in Parkinson’s disease patients. The data showed that the antibodies effectively engage with aggregated alpha-synuclein, a toxic protein associated with PD,...

By Daniella Parra ProSomnus, Inc. (NASDAQ: OSA) said it plans to conduct a clinical trial comparing its precision oral appliance therapy and hypoglossal nerve stimulation for severe obstructive sleep apnea treatment. This follows positive preliminary data from a study that...

By Daniella Parra Eterna Therapeutics Inc. (Nasdaq: ERNA) announced the appointment of Brant Binder, a seasoned leader and entrepreneur with more than 25 years of strategic expertise building and growing biotechnology companies and Richard Wagner, Ph.D., a biotechnology entrepreneur with more than...

By Daniella Parra A recent survey by ProSomnus, Inc. (NASDAQ: OSA) and Proedge revealed that 71% of snorers have never sought medical advice. Obstructives Sleep Apnea (OSA) is a recurring airway collapse during sleep, linked to serious comorbidities. Over one...

By Daniella Parra Prenetics Global Limited (NASDAQ: PRE) and Prof. Dennis Lo, the Li Ka Shing Professor of Medicine of the Chinese University of Hong Kong have formed a joint venture named Insighta, aiming to revolutionize multi-cancer early detection screening....

By Daniella Parra Swiss life sciences company Lunaphore Technologies SA has agreed to be acquired by Bio-Techne Corporation, (NASDAQ:TECH) a global provider of tools and reagents for research and diagnostics. Lunaphore’s advanced microfluidic technology enables the analysis of biomarkers in...

By Daniella Parra Vaxxinity (Nasdaq: VAXX) has revealed encouraging findings from the Phase 1b clinical trial of UB-312, their vaccine candidate targeting alpha-synuclein for the treatment and prevention of Parkinson’s disease (PD) and other synucleinopathies. The study demonstrated that UB-312...